In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Aclarion, Inc. (ACON – Research Report), with a price target of $3.00. The company’s shares opened today at $1.11.
According to TipRanks, Vendetti is a 3-star analyst with an average return of 1.1% and a 35.42% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Aethlon Medical, ReShape Lifesciences, and Nephros.
Aclarion, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See today’s best-performing stocks on TipRanks >>
ACON market cap is currently $9.46M and has a P/E ratio of -0.97.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
Read More on ACON:
- Sachem Capital Corp. Announces Closing of Public Offering of $35.0 Million of 8.00% Notes
- LiveToBeHappy Reports Record Second Quarter 2022 Results; 2022 YTD Revenues Increase 35% YoY to $5.4 Million
- Net Asset Value(s)
- Mizuho Securities Remains a Buy on BridgeBio Pharma (BBIO)
- H.C. Wainwright Keeps Their Hold Rating on BerGenBio AS (BRRGF)
